Copyright
©The Author(s) 2024.
World J Stem Cells. Jun 26, 2024; 16(6): 641-655
Published online Jun 26, 2024. doi: 10.4252/wjsc.v16.i6.641
Published online Jun 26, 2024. doi: 10.4252/wjsc.v16.i6.641
n | Mean | SD | Mean rank | χ2 | df | P value | |
Preoperative | 6 | 18.83 | 5.04 | 5.58 | 28.462 | 5 | 0.000 |
Postoperative 1st wk | 6 | 18.50 | 4.85 | 5.25 | |||
Postoperative 1st month | 6 | 16.33 | 4.68 | 3.83 | |||
Postoperative 2nd month | 6 | 15.83 | 5.04 | 3.25 | |||
Postoperative 4th month | 6 | 14.33 | 4.18 | 1.83 | |||
Postoperative 1st yr | 6 | 13.00 | 4.60 | 1.25 |
- Citation: Kabatas S, Civelek E, Boyalı O, Sezen GB, Ozdemir O, Bahar-Ozdemir Y, Kaplan N, Savrunlu EC, Karaöz E. Safety and efficiency of Wharton’s Jelly-derived mesenchymal stem cell administration in patients with traumatic brain injury: First results of a phase I study. World J Stem Cells 2024; 16(6): 641-655
- URL: https://www.wjgnet.com/1948-0210/full/v16/i6/641.htm
- DOI: https://dx.doi.org/10.4252/wjsc.v16.i6.641